The phase III TULIP study met its primary endpoint of progression-free survival in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer—demonstrating a statistically significant improvement over physician’s choice.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe